logo
Медицинский вестник
Северного Кавказа
Научно-практический журнал
Зарегистрирован в Федеральной службе
по надзору за соблюдением законодательства
в сфере массовых коммуникаций
и охране культурного наследия
ПИ №ФС77-26521 от 7 декабря 2006 года
ISSN 2073-8137
rus
русский
eng
english

Поиск по сайту




Адрес редакции
355017, Ставрополь, улица Мира, 310.

Телефоны
(8652) 35-25-11, 35-32-29.

E-mail
medvestnik@stgmu.ru

Рейтинг@Mail.ru

Неалкогольная жировая болезнь печени и сахарный диабет в контексте диабетической болезни печени: возможности ассоциированной терапии

[Обзор]
Маев Игорь Вениаминович; Осадчук Максим Михайлович; Осадчук Михаил Алексеевич; Миронова Екатерина Дмитриевна;

Рассматривается неалкогольная жировая болезнь печени (НАЖБП), ассоциированная с сахарным диабетом (СД), в контексте социально-экономических, этиопатогенетических, прогностических и лечебных позиций. Наличие единых этиопатогенетических факторов дает возможность высказать мнение, что НАЖБП может являться самостоятельным предиктором СД, усугубляющим течение сердечно-сосудистых заболеваний, микро- и макроангиопатий. Прогрессирование НАЖБП на фоне СД диктует необходимость оценки применения антидиабетических препаратов для достижения ремиссии и регресса воспалительных и фибротических изменений, предотвращения развития цирроза печени и гепатоцеллюлярной карциномы.

Скачать

Список литературы:
1. Neuschwander-Tetri B. A. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):45. https://doi.org/10.1186/s12916-017-0806-8
2. Eslam M., Sanyal A. J., George J., International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014. e1. https://doi.org/10.1053/j.gastro.2019.11.312
3. Younossi Z. M., Koenig A. B., Abdelatif D. [et al.]. Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. https://doi.org/10.1002/hep.28431
4. Snyder H. S., Sakaan S. A., March K. L. [et al.]. Nonalcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies. J. Clin. Transl. Hepatol. 2018;6(2):168-174. https://doi.org/10.14218/JCTH.2017.00050
5. Zhang M., Lin S., Wang M.-F. [et al.]. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? BMC Gastroenterol. 2020;20(1):139. https://doi.org/10.1186/s12876-020-01278-z
6. Williamson R. M., Price J. F., Glancy S. [et al.]. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34(5):1139-1144. https://doi.org/10.2337/dc10-2229
7. Portillo-Sanchez P., Bril F., Maximos M. [et al.]. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. J. Clin. Endocrinol. Metab. 2015;100(6):2231-2238. https://doi.org/10.1210/jc.2015-1966
8. Armstrong M. J., Hazlehurst J. M., Parker R. [et al.]. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM. 2014;107(1):33-41. https://doi.org/10.1093/qjmed/hct198
9. Satapathy S. K., Sanyal A. J. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin. Liver Dis. 2015;35(3):221-235. https://doi.org/10.1055/s-0035-1562943
10. McPherson S., Hardy T., Henderson E. [et al.]. Evidence of NAFLD progression from steatosis to fibrosingsteatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 2015;62(5):1148-1155. https://doi.org/10.1016/j.jhep.2014.11.034
11. Sumida Y., Yoneda M., Tokushige K. [et al.]. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int. J. Mol. Sci. 2020;21(6). https://doi.org/10.3390/ijms21061907
12. Younossi Z. M., Blissett D., Blissett R. [et al.]. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577-1586. https://doi.org/10.1002/hep.28785
13. Jäger S., Jacobs S., Kröger J. [et al.]. Association between the Fatty Liver Index and Risk of Type 2 Diabetes in the EPIC-Potsdam Study. PLoS One. 2015;10(4). https://doi.org/10.1371/journal.pone.0124749
14. Singal A. K., Hasanin M., Kaif M. [et al.]. Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States. Transplantation. 2016;100(3):607-612. https://doi.org/10.1097/TP.0000000000000945
15. Targher G., Byrne C. D. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J. Clin. Endocrinol. Metab. 2013;98(2):483-495. https://doi.org/10.1210/jc.2012-3093
16. Kantartzis K., Peter A., Machicao F. [et al.]. Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene. Diabetes. 2009;58(11):2616-2623. https://doi.org/10.2337/db09-0279
17. Chu H., Duan Y., Yang L. [et al.]. Small metabolites, possible big changes: a microbiota-centered view of nonalcoholic fatty liver disease. Gut. 2019;68(2):359-370. https://doi.org/10.1136/gutjnl-2018-316307
18. Fruci B., Giuliano S., Mazza A. [et al.]. Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. Int. J. Mol. Sci. 2013;14(11):22933-22966. https://doi.org/10.3390/ijms141122933
19. Llovet J. M., Zucman-Rossi J., Pikarsky E. [et al.]. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 2016;2:16018. https://doi.org/10.1038/nrdp.2016.18
20. Vilar-Gomez E., Martinez-Perez Y., Calzadilla-Bertot L. [et al.]. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5; quiz e14-15. https://doi.org/10.1053/j.gastro.2015.04.005
21. Angulo P., Kleiner D. E., Dam-Larsen S. [et al.]. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-397.e10. https://doi.org/10.1053/j.gastro.2015.04.043
22. Singh S., Allen A. M., Wang Z. [et al.]. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 2015;13(4):643-654. e1-9; quiz e39-40. https://doi.org/10.1016/j.cgh.2014.04.014
23. Chalasani N., Younossi Z., Lavine J. E. [et al.]. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. https://doi.org/10.1002/hep.29367
24. Choudhary N. S., Saraf N., Saigal S. [et al.]. Rapid Reversal of Liver Steatosis With Life Style Modification in Highly Motivated Liver Donors. J. Clin. Exp. Hepatol. 2015;5(2):123-126. https://doi.org/10.1016/j.jceh.2015.04.002
25. Hallsworth K., Thoma C., Hollingsworth K. G. [et al.]. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin. Sci. 2015;129(12):1097-1105. https://doi.org/10.1042/CS20150308
26. Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 2017;67(4):829-846. https://doi.org/10.1016/j.jhep.2017.05.016
27. Davies M. J., D’Alessio D. A., Fradkin J. [et al.]. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. https://doi.org/10.2337/dci18-0033
28. Watanabe S., Hashimoto E., Ikejima K. [et al.]. Evidencebased clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol. Res. 2015;45(4):363-377. https://doi.org/10.1111/hepr.12511
29. Younossi Z., Tacke F., Arrese M. [et al.]. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672-2682. https://doi.org/10.1002/hep.30251
30. Tang A., Rabasa-Lhoret R., Castel H. [et al.]. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care. 2015;38(7):1339-1346. https://doi.org/10.2337/dc14-2548
31. Goh GB-B., Pagadala M. R., Dasarathy J. [et al.]. Diabetes Mellitus, Insulin, Sulfonylurea and Advanced Fibrosis in Non- Alcoholic Fatty Liver Disease. Published online 2014. https://doi.org/10.4172/2155-6156.1000410
32. Zhou G., Myers R., Li Y. [et al.]. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001;108(8):1167-1174. https://doi.org/10.1172/JCI13505
33. Wu H., Esteve E., Tremaroli V. [et al.]. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 2017;23(7):850-858. https://doi.org/10.1038/nm.4345
34. Huang M.-Y., Chung C.-H., Chang W.-K. [et al.]. The role of thiazolidinediones in hepatocellular carcinoma risk reduction: a population-based cohort study in Taiwan. Am. J. Cancer Res. 2017;7(7):1606-1616.
35. Van Wagner L. B., Rinella M. E. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap. Adv. Gastroenterol. 2011;4(4):249-263. https://doi.org/10.1177/1756283X11403809
36. Musso G., Cassader M., Paschetta E. [et al.]. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis. JAMA Intern. Med. 2017;177(5):633-640. https://doi.org/10.1001/jamainternmed.2016.9607
37. Chalasani N., Younossi Z., Lavine J. E. [et al.]. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-2023. https://doi.org/10.1002/hep.25762
38. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388-1402. https://doi.org/10.1016/j.jhep.2015.11.004
39. Viscoli C. M., Inzucchi S. E., Young L. H. [et al.]. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. J. Clin. Endocrinol. Metab. 2017;102(3):914-922. https://doi.org/10.1210/jc.2016-3237
40. Abrahami D., Douros A., Yin H. [et al.]. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 2018;363:k4880. https://doi.org/10.1136/bmj.k4880
41. Abrahami D., Douros A., Yin H. [et al.]. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ. 2018;360:k872. https://doi.org/10.1136/bmj.k872
42. Sumida Y., Yoneda M., Tokushige K. [et al.]. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. Int. J. Mol. Sci. 2020;21(6). https://doi.org/10.3390/ijms21061907
43. Ao N., Yang J., Wang X. [et al.]. Glucagon-like peptide-1 preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway. Hepatol. Res. 2016;46(4):343-353. https://doi.org/10.1111/hepr.12551
44. Armstrong M. J., Gaunt P., Aithal G. P. [et al.]. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-690. https://doi.org/10.1016/S0140-6736(15)00803-X
45. Eguchi Y., Kitajima Y., Hyogo H. [et al.]. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol. Res. 2015;45(3):269-278. https://doi.org/10.1111/hepr.12351
46. Cusi K., Sattar N., García-Pérez L.-E. [et al.]. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diabet. Med. 2018;35(10):1434-1439. https://doi.org/10.1111/dme.13697
47. Gerstein H. C., Colhoun H. M., Dagenais G. R. [et al.]. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. https://doi.org/10.1016/S0140-6736(19)31149-3
48. Marso S. P., Bain S. C., Consoli A. [et al.]. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med. 2016;375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141
49. Newsome P., Francque S., Harrison S. [et al.]. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment. Pharmacol. Ther. 2019;50(2):193-203. https://doi.org/10.1111/apt.15316
50. Pratley R. E., Aroda V. R., Lingvay I. [et al.]. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. https://doi.org/10.1016/S2213-8587(18)30024-X
51. Camastra S., Astiarraga B., Tura A. [et al.]. Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients. Diabetes Obes. Metab. 2017;19(3):412-420. https://doi.org/10.1111/dom.12836
52. Seko Y., Nishikawa T., Umemura A. [et al.]. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis. Diabetes Metab. Syndr. Obes. 2018;11:835-843. https://doi.org/10.2147/DMSO.S184767
53. Shibuya T., Fushimi N., Kawai M. [et al.]. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study. Diabetes Obes. Metab. 2018;20(2):438-442. https://doi.org/10.1111/dom.13061
54. Ito D., Shimizu S., Inoue K. [et al.]. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2017;40(10):1364-1372. https://doi.org/10.2337/dc17-0518
55. Yang Z.-X., Shen W., Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol. Int. 2010;4(4):741-748. https://doi.org/10.1007/s12072-010-9202-6
56. Tanaka N., Kimura T., Fujimori N. [et al.]. Current status, problems, and perspectives of non-alcoholic fatty liver disease research. World J. Gastroenterol. 2019;25(2):163-177. https://doi.org/10.3748/wjg.v25.i2.163

Ключевые слова: неалкогольная жировая болезнь печени, сахарный диабет, антидиабетические препараты, метформин, тиазолидиндионы, агонисты рецептора глюкагоноподобного пептида 1, ингибиторы дипептидилпептидазы 4, ингибиторы котранспортера 2 натрия/глюкозы


Учредители:
Ставропольская государственная медицинская академия
Государственный научно-исследовательский институт курортологии
Пятигорская государственная фармацевтическая академия